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Previous studies on smokeless tobacco use and head and neck cancer (HNC) have found inconsistent and
often imprecise estimates, with limited control for cigarette smoking. Using pooled data from 11 US case-control
studies (1981–2006) of oral, pharyngeal, and laryngeal cancers (6,772 cases and 8,375 controls) in the
International Head and Neck Cancer Epidemiology (INHANCE) Consortium, we applied hierarchical logistic
regression to estimate odds ratios and 95% confidence intervals for ever use, frequency of use, and duration of
use of snuff and chewing tobacco separately for never and ever cigarette smokers. Ever use (versus never use)
of snuff was strongly associated with HNC among never cigarette smokers (odds ratio (OR) = 1.71, 95% confi-
dence interval (CI): 1.08, 2.70), particularly for oral cavity cancers (OR = 3.01, 95% CI: 1.63, 5.55). Although
ever (versus never) tobacco chewing was weakly associated with HNC among never cigarette smokers (OR =
1.20, 95% CI: 0.81, 1.77), analyses restricted to cancers of the oral cavity showed a stronger association (OR =
1.81, 95% CI: 1.04, 3.17). Few or no associations between each type of smokeless tobacco and HNC were
observed among ever cigarette smokers, possibly reflecting residual confounding by smoking. Smokeless
tobacco use appears to be associated with HNC, especially oral cancers, with snuff being more strongly associ-
ated than chewing tobacco.
chewing tobacco; head and neck neoplasms; snuff; tobacco, smokeless
Abbreviations: CI, confidence interval; HNC, head and neck cancer; ICD-10, International Classification of Diseases, Tenth
Revision; INHANCE, International Head and Neck Cancer Epidemiology; OR, odds ratio.
Editor’s note: An invited commentary on this article ap-
pears on page 717.
Head and neck cancer (HNC) encompasses tumors of
the oral cavity, pharynx, and larynx and accounts for
400,000–600,000 new cancer cases and 200,000–300,000
deaths globally each year (1–4). In the United States, esti-
mates of HNC incidence and mortality for 2015 were
59,340 new cases and 12,290 deaths (5). More than 90%
of HNCs are squamous cell carcinomas (2). Associations
between smoking tobacco products (cigarettes, cigars, and
pipes) and HNC have been previously described in the
International Head and Neck Cancer Epidemiology
(INHANCE) Consortium, with all 3 smoking tobacco prod-
ucts independently contributing to an elevated risk of HNC
(6). While the prevalence of cigarette smoking has declined
in the United States in recent years (22.2% in 2005 vs.
19.1% in 2010), use of smokeless tobacco has slightly,
though not significantly, increased (prevalence of 2.7% in
2005 vs. 3.0% in 2010) (7). The overall prevalence of
smokeless tobacco use in the United States is 10 times the
Healthy People 2020 target of 0.3% and therefore remains
an important public health concern (7). Like smoking
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tobacco products, smokeless tobacco products contain
numerous carcinogens, including several tobacco-specific
N-nitrosamines (8, 9). The International Agency for Research
on Cancer has concluded that there is sufficient evidence of
carcinogenicity for smokeless tobacco (8).
However, previous epidemiologic studies on smokeless
tobacco and HNC in the United States have produced
mixed results, with some investigators reporting elevated
risk and others near-null estimates (8–10). Given the rela-
tively small sample sizes of previous studies, estimates for
ever use of smokeless tobacco products were often impre-
cise, and frequency and duration of use, as well as exclu-
sive use, of smokeless tobacco products was largely
unexplored (8–10). Further, some studies had limited in-
formation on other lifestyle factors, particularly cigarette
smoking (8–10).
Using data from US studies in the INHANCE Con-
sortium, we were able to more precisely estimate associa-
tions between smokeless tobacco products and HNC,
including associations for exclusive use of smokeless
tobacco products and associations with specific tumor sites.
METHODS
Study design
As of June 2014, the INHANCE Consortium (http://
www.inhance.utah.edu/) had pooled data from 35 case-
control studies of HNC (data version 1.5). Information
about tobacco-chewing and snuff use was available from a
study in Puerto Rico (11), from Indian research centers in
an international study (12), and from most (12 out of 15)
US studies (13–25). European, Asian, and South American
studies that participate in the INHANCE Consortium did
not ascertain information on smokeless tobacco use, since
such behaviors are not common in those areas, except in
Nordic countries, which are not currently represented in
INHANCE. No individuals reported using snuff in the
study from Puerto Rico; use of chewing tobacco was infre-
quent and therefore was previously analyzed in combination
with other noncigarette forms of tobacco (11). Although
Indian research centers in the international study (12)
collected information on smokeless tobacco use, the prod-
ucts used in those centers (e.g., paan, a preparation contain-
ing areca nut and betel leaf) differed from those used in
other regions of the world, and an analysis of the data from
the Indian centers was previously published (investigators
reported an increased risk of HNC among paan chewers (8,
9, 12)). Therefore, we considered only US studies in the
present analysis.
We further excluded a study from Tampa, Florida (25),
because information on chewing tobacco and snuff use was
reported jointly in that study. The study from Boston,
Massachusetts (14) only ascertained information on chew-
ing tobacco and was therefore excluded from analyses of
snuff. In addition, persons with missing demographic data
on sex, age, race/ethnicity, or subtype of cancer (66 cases
and 51 controls) or missing behavioral data on frequency
of alcohol drinking or duration of cigarette, cigar, or pipe
smoking (463 cases and 363 controls) were excluded from
all analyses, since the models adjusted for these variables.
Therefore, our analysis included 6,772 cases and 8,375
controls from 11 studies conducted in the following loca-
tions: Seattle, Washington (1985–1989 (18) and 1990–
1995 (15)); the state of Iowa (1993–2006) (19); Los
Angeles, California (1999–2004) (20); Houston, Texas
(2001–2006) (21); Boston, Massachusetts (1999–2003)
(14); Baltimore, Maryland (2000–2005) (22); the state of
North Carolina (a hospital-based study (1994–1997) (23)
and a population-based study (2002–2006) (13)); New
York, New York (Memorial Sloan Kettering Cancer Center
(1992–1994) (24)); the state of New York and other loca-
tions (a multicenter study of hospital patients in New York
State, Illinois, Michigan, and Pennsylvania (1981–1990))
(17)); and nationwide (a multicenter study with centers in
Atlanta, Georgia; Los Angeles County, California; the state
of New Jersey; and Santa Clara and San Mateo counties,
California (1983–1984)) (16).
Descriptions of these studies, including definitions of
smokeless tobacco use, are provided in Web Table 1 (avail-
able at http://aje.oxfordjournals.org/). Most studies were
hospital-based, with cases and controls frequency-matched
by age and sex. Information on ever use of chewing
tobacco and snuff, frequency of use (number of times per
day), and duration of use (in years) was ascertained sepa-
rately in each study. However, information on frequency of
smokeless tobacco use in the Seattle (15, 18) and New
York multicenter (17) studies was not available or was not
easily standardized with data from other studies; therefore,
we excluded these studies from analyses of frequency.
Pooling methods have been previously described (26, 27).
Tumor sites were categorized according to the International
Classification of Diseases for Oncology, Second Edition,
the International Classification of Diseases, Ninth Revision,
or the International Classification of Diseases, Tenth
Revision (ICD-10) (26, 28–30). Cancers of the oral cavity,
oropharynx, hypopharynx, oral cavity or pharynx overlap-
ping or not otherwise specified, and larynx were included
(ICD-10 codes are provided in a footnote to Table 1).
Among oral cavity cancers, cancers of the gum, cheek
mucosa, and vestibule of the mouth (ICD-10 codes C03 and
C06) were also analyzed as a subset. Cancers of the salivary
glands, lip, nasopharynx, and esophagus were excluded.
Informed consent and institutional review board approval
were obtained at each study center, and all identifying
information was removed before data were pooled. In addi-
tion, this analysis was approved by the institutional review
board at the University of North Carolina.
Statistical analysis
We estimated odds ratios and 95% confidence intervals
for ever use of each smokeless tobacco product, with never
users of that same product serving as the referent group,
using hierarchical logistic regression with study centers as
a random effect. In addition, levels of frequency and dura-
tion for each smokeless tobacco product were modeled
using indicator variables. Linear trends in frequency and
duration were assessed through P values obtained from
modeling the continuous forms of those variables. All
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analyses were performed in SAS, version 9.2 (SAS Institute,
Inc., Cary, North Carolina), using the proc nlmixed
procedure (31).
Odds ratios were stratified by ever cigarette smoking and
were adjusted for sex, age, race/ethnicity, education, fre-
quency of alcohol use, duration of cigarette smoking,
Table 1. Characteristics of Head and Neck Cancer Cases
and Controls From 11 US Studies in the INHANCE Consortium,
1981–2006
Characteristic
Cases
(n = 6,772)
Controls
(n = 8,375)
No. % No. %
Study location (reference no.)a
Seattle, Washington (15, 18)b 387 5.71 601 7.18
Iowa (19) 532 7.86 749 8.94
Los Angeles, California (20) 415 6.13 999 11.93
Houston, Texas (21) 826 12.20 865 10.33
Boston, Massachusetts (14) 500 7.38 630 7.52
Baltimore, Maryland (22) 203 3.00 197 2.35
North Carolina, 1994–1997 (23) 176 2.60 202 2.41
North Carolina, 2002–2006 (13) 1,317 19.45 1,370 16.36
New York, New York
(MSKCC) (24)
99 1.46 134 1.60
New York State
(multicenter) (17)
1,237 18.27 1,379 16.47
United States (multicenter) (16)c 1,080 15.95 1,249 14.91
Age group, years
17–39 300 4.43 564 6.73
40–44 363 5.36 513 6.13
45–49 717 10.59 821 9.80
50–54 1,026 15.15 1,270 15.16
55–59 1,241 18.33 1,485 17.73
60–64 1,118 16.51 1,247 14.89
65–69 895 13.22 1,113 13.29
70–74 625 9.23 784 9.36
75–94 487 7.19 578 6.90
Race/ethnicity
Non-Hispanic white 5,554 82.01 6,998 83.56
Black 892 13.17 834 9.96
Hispanic/Latino 211 3.12 394 4.70
Asian/Pacific Islander 54 0.80 91 1.09
Other 61 0.90 58 0.69
Sex
Male 4,891 72.22 5,666 67.65
Female 1,881 27.78 2,709 32.35
Educational leveld
No formal education 7 0.10 5 0.06
Less than junior high school 455 6.72 376 4.49
Some high school 1,478 21.83 1,142 13.64
High school graduate 1,609 23.76 1,664 19.87
Vocational school, some
college
1,927 28.46 2,734 32.64
College graduate/postgraduate 1,294 19.11 2,453 29.29
Missing data 2 0.03 1 0.01
Cigarette smoking
Never smoker 1,257 18.56 3,333 39.80
Ever smoker 5,515 81.44 5,042 60.20
Table continues
Table 1. Continued
Characteristic
Cases
(n = 6,772)
Controls
(n = 8,375)
No. % No. %
Cigar smoking
Never smoker 6,072 89.66 7,540 90.30
Ever smoker 700 10.34 835 9.97
Pipe smoking
Never smoker 6,095 90.00 7,415 88.54
Ever smoker 677 10.00 960 11.46
Alcohol drinking
Never drinker 921 13.60 2,113 25.23
Ever drinker 5,851 86.40 6,262 74.77
Tumor sitee
Oral cavity 2,034 30.04
Oropharynx 2,373 35.04
Hypopharynx 366 5.40
Oral/pharynx NOS 743 10.97
Larynx 1,256 18.55
Abbreviations: INHANCE, International Head and Neck Cancer
Epidemiology; MSKCC, Memorial Sloan Kettering Cancer Center;
NOS, not otherwise specified.
a Studies of smokeless tobacco use comprised primarily US stud-
ies in version 1.5 of the INHANCE Consortium data set, and only US
studies were analyzed. A study from Tampa, Florida (25), was
excluded because information on chewing tobacco and snuff use
was reported jointly. The publications referenced are representative
of each study and do not necessarily report estimates for smokeless
tobacco.
b Data for the Seattle study were collected at 2 time points: 1985–
1989 (271 cases and 464 controls; men only) (18) and 1990–1995
(116 cases and 137 controls; men and women) (15).
c Data for the US multicenter study (16) were collected at 4 study
centers: metropolitan Atlanta, Georgia (129 cases and 136 controls);
Los Angeles County, California (407 cases and 514 controls); the
state of New Jersey (480 cases and 460 controls); and Santa Clara
and San Mateo counties, California (64 cases and 139 controls).
d Educational information in this table represents actual counts
and percentages. However, missing education values for 3 indivi-
duals were imputed a single time based on age, sex, race/ethnicity,
study center, and case-control status.
e International Classification of Diseases, Tenth Revision, codes:
oral cavity—codes C00.3–C00.9, C02.0–C02.3, C03.0, C03.1, C03.9,
C04.0, C04.1, C04.8, C04.9, C05.0, C06.0–C06.2, C06.8, and C06.9;
oropharynx—codes C01.9, C02.4, C05.1, C05.2, C09.0, C09.1, C09.8,
C09.9, C10.0–C10.4, C10.8, and C10.9; hypopharynx—codes C12.9,
C13.0–C13.2, C13.8, and C13.9; oral cavity or pharynx overlapping or
NOS—codes C02.8, C02.9, C05.8, C05.9, C14.0, C14.2, and C14.8;
larynx—codes C32.0–C32.3 and C32.8–C32.9.
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duration of cigar smoking, and duration of pipe smoking,
as specified in the table footnotes. Since the study from
Boston (14) did not ascertain information on snuff use,
odds ratios for chewing tobacco were not adjusted for snuff
use. Likewise, odds ratios for snuff use were not adjusted
for chewing tobacco. Finally, we conducted analyses strati-
fied by tumor site, sex, age, and race/ethnicity.
Associations with exclusive use of each smokeless
tobacco product, as well as joint use with smoking tobacco
products, were also modeled. Exclusive and joint use of
product(s) was defined as ever use of the specified tobacco
product(s) and never use of all other tobacco product(s).
RESULTS
Study participants were predominantly from the US mul-
ticenter study (16) (16.0% of cases and 14.9% of controls),
the New York multicenter study (17) (18.3% of cases and
16.5% of controls), and the North Carolina 2002–2006
study (13) (19.5% of cases and 16.4% of controls)
(Table 1). Half of the cases (50.0%) and controls (47.8%)
were between the ages of 50 and 65 years, and the majority
of participants were non-Hispanic white (82.0% of cases
and 83.6% of controls). Over two-thirds of the cases (72.2%)
and controls (67.7%) were male.
Among never cigarette smokers, odds ratios for smoke-
less tobacco use and HNC were 1.71 (95% confidence inter-
val (CI): 1.08, 2.70) for ever users of snuff compared with
never users and 1.20 (95% CI: 0.81, 1.77) for ever tobacco
chewers compared with never chewers (Tables 2 and 3).
When duration and frequency of smokeless tobacco use
were considered, HNC risk increased with increasing dura-
tion of snuff use (Ptrend = 0.007), though no other mono-
tonic trends were noted among never cigarette smokers.
Among ever cigarette smokers, odds ratios were 0.83 (95%
CI: 0.63, 1.08) for ever using snuff and 0.96 (95% CI: 0.79,
1.17) for ever chewing tobacco (Tables 2 and 3). Estimates
were near null across strata of frequency and duration of
snuff use and chewing tobacco use among ever cigarette
smokers. When we stratified ever cigarette smokers into for-
mer and current smokers, estimates were similar to each
other and remained near null (Web Tables 2 and 3).
Table 2. Odds Ratios for Head and Neck Cancer According to Snuff Use and Cigarette Smoking Among US Studies in the INHANCE
Consortium, 1981–2006a
Snuff Use Variable
Never Cigarette Smokers Ever Cigarette Smokers
No. of Cases No. of Controls ORb 95% CI No. of Cases No. of Controls ORc 95% CI
Snuff use status
Never user 1,128 3,056 1.00 Referent 4,930 4,462 1.00 Referent
Ever user 44 62 1.71 1.08, 2.70 167 164 0.83 0.63, 1.08
Missing data 0 0 3 1
Frequency of use, times/dayd
Never user 865 2,365 1.00 Referent 3,594 3,198 1.00 Referent
>0–≤2e 28 45 1.47 0.82, 2.62 95 104 0.69 0.48, 1.00
>2 9 10 1.40 0.48, 4.06 38 37 0.75 0.42, 1.34
Missing data 4 2 15 4
Ptrend
f 0.31 0.20
Duration of use, years
Never user 1,128 3,056 1.00 Referent 4,930 4,462 1.00 Referent
>0–≤20 20 28 1.50 0.77, 2.91 134 140 0.79 0.59, 1.06
>20 22 33 1.78 0.95, 3.36 31 22 1.06 0.54, 2.09
Missing data 2 1 5 3
Ptrend
f 0.007 0.31
Abbreviations: INHANCE, International Head and Neck Cancer Epidemiology; CI, confidence interval; OR, odds ratio.
a The Boston study (14) (500 cases and 630 controls) was excluded from analyses of snuff use because information on snuff use was not
available.
b Adjusted for sex, age (years), race/ethnicity (white, black, Hispanic, Asian and Pacific Islander, or other race/ethnicity), education (junior
high school or less, some high school, high school graduation, technical school or some college, and college graduation or more), frequency of
alcohol use (mL/day, truncated at the 95th percentile among alcohol drinkers to account for extreme values), duration of cigar smoking (years),
and duration of pipe smoking (years).
c Adjusted for the same variables as those for never cigarette smokers, plus duration of cigarette smoking (years).
d The New York multicenter (17) and Seattle (15, 18) studies (1,624 cases and 1,980 controls) were excluded from analyses of snuff use fre-
quency because information on frequency was not available or was not easily standardized with data from other studies.
e The majority of cases and controls in the >0–≤2 times/day category used snuff once or fewer times per day.
f P for linear trend obtained from modeling the continuous form of the frequency or duration variable.
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When associations between smokeless tobacco use and spe-
cific HNC tumor sites among never cigarette smokers were
considered, the highest-magnitude odds ratios were observed
for tumors of the oral cavity (Tables 4 and 5). Specifically, the
odds ratios for ever snuff use and ever tobacco chewing and
cancers of the oral cavity were 3.01 (95% CI: 1.63, 5.55) and
1.81 (95% CI: 1.04, 3.17), respectively. When tumors were
further restricted to cancers of the gum, the magnitude of odds
ratios among never cigarette smokers increased, but estimates
were very imprecise due to small cell counts (for snuff use,
OR = 12.7, 95% CI: 4.76, 33.7; for tobacco chewing, OR =
3.07, 95% CI: 1.10, 8.59). Among ever cigarette smokers, we
observed little association between snuff use or tobacco chew-
ing and risk of oral cavity cancer (Tables 4 and 5). When we
considered only HNC with squamous cell carcinoma histol-
ogy, odds ratios were similar to the overall HNC estimates for
each smokeless tobacco product (Tables 4 and 5). Smokeless
tobacco–HNC odds ratios stratified by age, sex, and race/
ethnicity were imprecise, though estimates among never
cigarette smokers appeared elevated in both age groups, in
whites and nonwhites, and among females but not males
(Tables 4 and 5).
Since analyses stratified by cigarette smoking were
adjusted for, but not restricted by, use of other smoking
tobacco products, we also estimated odds ratios for exclu-
sive tobacco chewing and exclusive snuff use compared
with never tobacco use. Odds ratios for exclusive snuff
users and exclusive tobacco chewers were 1.58 (95% CI:
0.86, 2.89) and 0.80 (95% CI: 0.40, 1.60), respectively
(Table 6). The odds ratio for joint users of chewing tobacco
and snuff was 2.08 (95% CI: 0.97, 4.45) (Table 6). Likewise,
odds ratios for joint users of smokeless and smoking tobacco
products were elevated (Table 6).
In sensitivity analyses of ever use of each smokeless
tobacco product, we investigated the influence of each
study center on the overall estimates by omitting one study
center at a time and reanalyzing the data. No single study
center appeared to substantially influence the odds ratios
for either ever snuff use or ever tobacco chewing (Web
Table 4). We also evaluated changes in odds ratios for ever
snuff use and ever tobacco chewing across different sets
of adjustment variables. In addition to the main models
described above, we considered 1) a reduced model that
did not adjust for duration of cigar smoking or duration of
Table 3. Odds Ratios for Head and Neck Cancer According to Tobacco Chewing and Cigarette Smoking Among US Studies in the INHANCE
Consortium, 1981–2006
Tobacco Chewing Variable
Never Cigarette Smokers Ever Cigarette Smokers
No. of Cases No. of Controls ORa 95% CI No. of Cases No. of Controls ORb 95% CI
Tobacco chewing status
Never user 1,196 3,237 1.00 Referent 5,130 4,719 1.00 Referent
Ever user 61 96 1.20 0.81, 1.77 382 322 0.96 0.79, 1.17
Missing data 0 0 3 1
Frequency of use, times/dayc
Never user 938 2,554 1.00 Referent 3,818 3,486 1.00 Referent
>0–≤2d 37 68 1.03 0.63, 1.70 272 226 0.90 0.71, 1.15
>2 13 12 1.53 0.60, 3.88 43 33 0.99 0.56, 1.75
Missing data 3 3 24 13
Ptrend
e 0.44 0.60
Duration of use, years
Never user 1,196 3,237 1.00 Referent 5,130 4,719 1.00 Referent
>0–≤20 29 46 1.23 0.72, 2.13 272 226 0.96 0.76, 1.20
>20 25 40 1.06 0.58, 1.92 73 67 0.88 0.58, 1.35
Missing data 7 10 40 30
Ptrend
e 0.56 0.38
Abbrevations: CI, confidence interval; INHANCE, International Head and Neck Cancer Epidemiology; OR, odds ratio.
a Adjusted for sex, age (years), race/ethnicity (white, black, Hispanic, Asian and Pacific Islander, or other race/ethnicity), education (junior
high school or less, some high school, high school graduation, technical school or some college, and college graduation or more), frequency of
alcohol use (mL/day, truncated at the 95th percentile among alcohol drinkers to account for extreme values), duration of cigar smoking (years),
and duration of pipe smoking (years).
b Adjusted for the same variables as those for never cigarette smokers, plus duration of cigarette smoking (years).
c The New York multicenter (17) and Seattle (15, 18) studies (1,624 cases and 1,980 controls) were excluded from analyses of chewing
tobacco frequency because information on frequency was not available or was not easily standardized with data from other studies.
d The majority of cases and controls in the >0–≤2 times/day category used chewing tobacco once or fewer times per day.
eP for linear trend obtained from modeling the continuous form of the frequency or duration variable.
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Table 4. Odds Ratios for Head and Neck Cancer According to Snuff Use and Cigarette Smoking, by Tumor Site, Sex, and Age, Among US
Studies in the INHANCE Consortium, 1981–2006a
Variable and
Snuff Use
Smoking Status
Never Cigarette Smoking Ever Cigarette Smoking
No. of Cases No. of Controls ORb 95% CI No. of Cases No. of Controls ORc 95% CI
Tumor Site
Oral cavity
Never user 379 3,056 1 Referent 1,479 4,462 1 Referent
Ever user 20 62 3.01 1.63, 5.55 43 164 0.86 0.57, 1.30
Missing data 0 0 0 1
Gum
Never user 52 3,056 1 Referent 241 4,462 1 Referent
Ever user 10 62 12.70 4.76, 33.7 8 164 1.15 0.45, 2.90
Missing data 0 0 0 1
Pharynx
Never user 499 3,056 1 Referent 1,888 4,462 1 Referent
Ever user 18 62 1.22 0.65, 2.27 74 164 0.94 0.67, 1.31
Missing data 0 0 1 1
Hypopharynxd
Never user 33 2,845 1 Referent 282 4,081 1 Referent
Ever user 3 59 3.00 0.66, 13.6 10 158 0.90 0.40, 2.03
Missing data 0 0 0 1
Oropharynx
Never user 466 3,056 1 Referent 1,606 4,462 1 Referent
Ever user 15 62 1.07 0.55, 2.08 64 164 0.94 0.67, 1.31
Missing data 0 0 1 1
Oral cavity/pharynx NOS
Never user 181 3,056 1 Referent 505 4,462 1 Referent
Ever user 4 62 0.90 0.27, 2.96 16 164 0.92 0.47, 1.82
Missing data 0 0 2 1
Larynxd
Never user 69 2,146 1 Referent 1,058 2,786 1 Referent
Ever user 2 50 —e — 34 136 0.65 0.52, 1.10
Missing data 0 0 0 1
SCC (all sites)
Never user 921 3,056 1 Referent 4,173 4,462 1 Referent
Ever user 39 62 1.60 1.00, 2.57 154 164 0.87 0.66, 1.16
Missing data 0 0 2 1
Demographic Factors
Sex
Female
Never user 391 1,344 1 Referent 1,301 1,161 1 Referent
Ever user 20 12 8.89 3.59, 22.0 23 9 0.92 0.35, 2.43
Missing data 0 0 2 0
Male
Never user 737 1,712 1 Referent 3,629 3,301 1 Referent
Ever user 24 50 0.86 0.49, 1.51 144 155 0.81 0.61, 1.07
Missing data 0 0 1 1
Table continues
Am J Epidemiol. 2016;184(10):703–716
708 Wyss et al.
pipe smoking and 2) a full model that further adjusted
chewing tobacco odds ratios for duration of snuff use and
vice versa. For the full model, the study from Boston (14)
was omitted since information on snuff use was not avail-
able. Among never cigarette smokers, estimates for snuff
use and HNC remained similarly elevated across models
(Web Table 5). However, the odds ratio for ever chewing
tobacco and HNC among never cigarette smokers varied
across models, ranging from 1.38 (95% CI: 0.94, 2.01) for
the reduced model to 1.00 (95% CI: 0.66, 1.52) for the
full model, which included duration of snuff use (Web
Table 6).
DISCUSSION
Previous estimates of the risk of HNC among smokeless
tobacco users in the United States have been varied and
hard to interpret due to low frequencies of use, inconsistent
definitions of exposures and outcomes, and insufficient
control for important confounders, such as cigarette smok-
ing (8–10). Two meta-analyses on smokeless tobacco use
and HNC in the United States have been published. In
2008, Boffetta et al. (32) conducted a meta-analysis of 9
estimates from 6 US studies (5 case-control studies on oral
cancer risk and 1 cohort study on oral cancer mortality), re-
porting a summary relative risk of 2.6 (95% CI: 1.3, 5.2).
In 2009, Lee and Hamling (33) published meta-analysis re-
sults showing a summary relative risk of 2.16 (95% CI:
1.55, 3.02), based on 31 estimates from 25 US studies (23
case-control studies on oropharyngeal cancer risk and 2
cohort studies on oropharyngeal cancer mortality). Both
Boffetta et al. and Lee and Hamling noted significant het-
erogeneity across estimates, likely reflecting the array of
methods used by individual studies to account for cigarette
smoking, among other differences (32, 33). In a subset of 5
Table 4. Continued
Variable and
Snuff Use
Smoking Status
Never Cigarette Smoking Ever Cigarette Smoking
No. of Cases No. of Controls ORb 95% CI No. of Cases No. of Controls ORc 95% CI
Age group, years
<45
Never user 214 520 1 Referent 380 465 1 Referent
Ever user 11 19 1.21 0.51, 2.87 24 28 0.96 0.48, 1.95
Missing data 0 0 1 0
≥45
Never user 914 2,536 1 Referent 4,550 3,997 1 Referent
Ever user 33 43 1.88 1.10, 3.21 143 136 0.82 0.61, 1.10
Missing data 0 0 2 1
Race/ethnicity
White
Never user 975 2,512 1 Referent 3,976 3,718 1 Referent
Ever user 33 47 1.48 0.88, 2.48 125 148 0.79 0.58, 1.05
Missing data 0 0 2 1
Nonwhite
Never user 153 544 1 Referent 954 744 1 Referent
Ever user 11 15 2.82 1.05, 7.57 42 16 1.23 0.59, 2.59
Missing data 0 0 1 0
Abbrevations: CI, confidence interval; INHANCE, International Head and Neck Cancer Epidemiology; NOS, not otherwise specified; OR,
odds ratio; SCC, squamous cell carcinoma.
a The Boston study (14) (500 cases and 630 controls) was excluded from analyses of snuff use because information on snuff use was not
available.
b Adjusted for sex, age (years), race/ethnicity (white, nonwhite), educational level (less than high school, high school or more), frequency of
alcohol use (mL/day, truncated at the 95th percentile among alcohol drinkers to account for extreme values), duration of cigar smoking use
(years), and duration of pipe smoking (years). ORs stratified by sex were not adjusted for sex. ORs stratified by race/ethnicity were not adjusted
for race/ethnicity.
c Adjusted for the same variables as those for never cigarette smokers, plus duration of cigarette smoking (years).
d Hypopharynx analyses did not include the Seattle study (15, 18) because information on tumors of the hypopharynx was not reported in
that study. Larynx analyses did not include the Seattle and US multicenter (16) studies because information on tumors of the larynx was not re-
ported in those studies.
e Unstable estimate.
Am J Epidemiol. 2016;184(10):703–716
Smokeless Tobacco and Head and Neck Cancer 709
Table 5. Odds Ratios for Head and Neck Cancer According to Chewing Tobacco Use and Cigarette Smoking Status, by Tumor Site, Sex,
and Age, Among US Studies in the INHANCE Consortium, 1981–2006
Variable and
Chewing Tobacco Use
Smoking Status
Never Cigarette Smoking Ever Cigarette Smoking
No. of Cases No. of Controls ORa 95% CI No. of Cases No. of Controls ORb 95% CI
Tumor Site
Oral cavity
Never user 398 3,237 1 Referent 1,533 4,719 1 Referent
Ever user 23 96 1.81 1.04, 3.17 80 322 0.87 0.64, 1.19
Missing data 0 0 0 1
Gum
Never user 59 3,237 1 Referent 267 4,719 1 Referent
Ever user 7 96 3.07 1.10, 8.59 16 322 0.85 0.45, 1.60
Missing data 0 0 0 1
Pharynx
Never user 536 3,237 1 Referent 2,034 4,719 1 Referent
Ever user 29 96 1.04 0.62, 1.73 138 322 0.93 0.72, 1.20
Missing data 0 0 2 1
Hypopharynxc
Never user 36 3,027 1 Referent 303 4,341 1 Referent
Ever user 5 92 1.71 0.45, 6.47 22 313 0.88 0.50, 1.54
Missing data 0 0 0 1
Oropharynx
Never user 500 3,237 1 Referent 1,731 4,719 1 Referent
Ever user 24 96 0.98 0.57, 1.68 116 322 0.94 0.72, 1.22
Missing data 0 0 2 1
Oral cavity/pharynx NOS
Never user 189 3,237 1 Referent 499 4,719 1 Referent
Ever user 5 96 0.75 0.26, 2.13 50 322 1.28 0.85, 1.92
Missing data 0 0 0 1
Larynxc
Never user 73 2,339 1 Referent 1,064 3,091 1 Referent
Ever user 4 72 —d — 114 246 1.11 0.79, 1.55
Missing data 0 0 1 1
SCC (all sites)
Never user 992 3,237 1 Referent 4,397 4,719 1 Referent
Ever user 53 96 1.17 0.78, 1.76 345 322 0.96 0.79, 1.18
Missing data 0 0 2 1
Demographic Factors
Sex
Female
Never user 444 1,430 1 Referent 1,410 1,264 1 Referent
Ever user 7 9 2.74 0.81, 9.23 20 6 2.03 0.63, 6.54
Missing data 0 0 0 0
Male
Never user 752 1,807 1 Referent 3,720 3,455 1 Referent
Ever user 54 87 1.07 0.71, 1.62 362 316 0.96 0.79, 1.17
Missing data 0 0 3 1
Table continues
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smokeless tobacco estimates restricted to never cigarette
smokers, Lee and Hamling reported a relative risk of 3.33
(95% CI: 1.76, 6.32) (33).
The 2007 International Agency for Research on Cancer
monograph on smokeless tobacco (8) and the 2012 update
of this report (9) discuss the methods and results of 25 US
studies which considered the relationship between smoke-
less tobacco and HNC (21 case-control studies and 1 cohort
study on HNC incidence and 3 cohort studies on HNC
mortality). Many of these studies were included in the
2 previous meta-analyses (32, 33). Recently, 2 additional
US studies on smokeless tobacco and HNC have been pub-
lished (13, 14). Of the 24 previous US studies on smokeless
tobacco use and HNC incidence, 1 study considered lip can-
cers (34) and 7 studies, published mostly before 1970, con-
sidered the proportions of participants who used smokeless
tobacco products (35–41), with many finding a significantly
higher proportion of cases who used smokeless tobacco
than controls (35, 37, 38, 41). We will specifically discuss
the results obtained from our pooled analysis within the
context of the similarities with and differences from the
remaining 16 US studies (13–18, 42–51). Ten of these pre-
vious studies are not represented in the INHANCE Consor-
tium (42–51), while 6 are represented (13–18).
Given the strong association between cigarette smoking
and HNC and the large proportions of cases and controls
who smoked cigarettes, we stratified smokeless tobacco es-
timates by cigarette smoking to obtain odds ratios for
smokeless tobacco use among persons not influenced by
active cigarette smoking. We also adjusted for other impor-
tant behaviors that may confound the relationship between
smokeless tobacco use and HNC (e.g., frequency of alco-
hol drinking and duration of cigar and pipe smoking).
Among never cigarette smokers, snuff use was strongly
associated with HNC, while chewing tobacco was weakly
associated with HNC.
Ideally, our chewing tobacco models would have adjusted
for duration of snuff use and the snuff models for duration
Table 5. Continued
Variable and
Chewing Tobacco Use
Smoking Status
Never Cigarette Smoking Ever Cigarette Smoking
No. of Cases No. of Controls ORa 95% CI No. of Cases No. of Controls ORb 95% CI
Age group, years
<45
Never user 224 548 1 Referent 400 486 1 Referent
Ever user 11 18 1.38 0.58, 3.29 27 25 1.18 0.59, 2.38
Missing data 0 0 1 0
≥45
Never user 972 2,689 1 Referent 4,730 4,233 1 Referent
Ever user 50 78 1.12 0.73, 1.73 355 297 0.98 0.80, 1.21
Missing data 0 0 2 1
Race/ethnicity
White
Never user 1,033 2,674 1 Referent 4,176 3,966 1 Referent
Ever user 51 79 1.20 0.79, 1.82 293 278 0.98 0.79, 1.21
Missing data 0 0 1 1
Nonwhite
Never user 163 563 1 Referent 954 753 1 Referent
Ever user 10 17 1.20 0.43, 3.37 89 44 1.01 0.62, 1.63
Missing data 0 0 2 0
Abbreviations: CI, confidence interval; INHANCE, International Head and Neck Cancer Epidemiology; NOS, not otherwise specified; OR,
odds ratio; SCC, squamous cell carcinoma.
a Adjusted for sex, age (years), race/ethnicity (white, nonwhite), educational level (less than high school, high school or more), frequency of
alcohol use (mL/day, truncated at the 95th percentile among alcohol drinkers to account for extreme values), duration of cigar smoking use
(years), and duration of pipe smoking (years). ORs stratified by sex were not adjusted for sex. ORs stratified by race/ethnicity were not adjusted
for race/ethnicity.
b Adjusted for same variables as those for never cigarette smokers, plus duration of cigarette smoking (years).
c Hypopharynx analyses did not include the Seattle study (15, 18) because information on tumors of the hypopharynx was not reported in
that study. Larynx analyses did not include the Seattle and US multicenter (16) studies because information on tumors of the larynx was not re-
ported in those studies.
d Unstable estimate.
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of tobacco chewing, but 1 study included in our analyses
did not ascertain information on snuff use. Therefore, our
primary models did not mutually adjust for the other smoke-
less tobacco behavior. However, sensitivity analyses omitting
the study from Boston (14), allowing further adjustment,
were explored. Snuff use remained strongly associated with
HNC when results were adjusted for chewing tobacco, but
estimates for chewing tobacco were attenuated towards the
null in models adjusting for snuff use.
Similarly to our study, 4 previous studies stratified
smokeless tobacco–HNC estimates by cigarette smoking,
finding elevated risk among nonsmokers. Winn et al. (45)
conducted a study of snuff use among females in North
Carolina. Among nonsmokers, odds ratios were elevated in
whites (OR = 4.2, 95% CI: 2.6, 6.7) and less so in African
Americans (OR = 1.5, 95% CI: 0.5, 4.8) (45). In another
study carried out among females in 4 US cities, Blot et al.
(16) also reported an elevated odds ratio for smokeless
tobacco use among nonsmokers (OR = 6.2, 95% CI: 1.9,
19.8). Among males in 8 US cities, Kabat et al. (46) reported
an unadjusted odds ratio of 2.25 (95% CI: 0.69, 7.34) among
nonsmokers. Finally, in the Boston study, Zhou et al. (14) re-
ported an odds ratio for smokeless tobacco among never ciga-
rette smokers of 4.21 (95% CI: 1.01, 17.57).
Among ever cigarette smokers, few or no positive asso-
ciations between chewing tobacco or snuff and HNC were
observed in our study. Although we adjusted smokeless
tobacco estimates among ever cigarette smokers for dura-
tion of cigarette smoking, the null chewing tobacco and
snuff results among ever cigarette smokers could have
been due to residual confounding attributable to cigarette
smoking (6). People who smoke cigarettes and use smoke-
less tobacco may differ from those who just use smokeless
tobacco with respect to the duration and frequency of use
of each product. Of the 4 previous studies which stratified
smokeless tobacco estimates by cigarette smoking, only
Winn et al. commented on smokeless tobacco among ever
cigarette smokers, reporting some evidence for elevated
HNC risk associated with snuff (45).
Previous studies which adjusted for cigarette smoking
without stratifying by cigarette smoking found mixed re-
sults for smokeless tobacco use and HNC, with estimates
ranging from near 0.5 to over 2.0 (13, 15, 42–44). Among
published articles that did not clearly specify adjustment
for or stratification by cigarette smoking, 4 studies found
elevated associations, with 2 studies reporting an insignifi-
cant risk (1 study provided an odds ratio while the other did
not) (48, 49) and 2 studies reporting stronger associations
Table 6. Odd Ratios for Head and Neck Cancer According to Exclusive and Joint Usea of Smokeless Tobacco Products (Chewing Tobacco
and Snuff) and Smoking Tobacco Products (Cigarettes, Cigars, and Pipes) Among US Studies in the INHANCE Consortium, 1981–2006b
Tobacco Use No. of Casesc No. of Controlsd ORe 95% CI
Never use of tobaccof 916 2,767 1.00 Referent
Only smoking productsg 4,812 4,443 2.47 2.23, 2.74
Only chewing tobacco 14 43 0.80 0.40, 1.60
Only snuff 24 32 1.58 0.86, 2.89
Chewing tobacco and snuff 16 18 2.08 0.97, 4.45
Chewing tobacco and smoking products 315 265 2.23 1.80, 2.77
Snuff and smoking products 89 98 1.78 1.26, 2.52
Chewing tobacco, snuff, and smoking products 82 78 1.77 1.22, 2.58
Missing data 4 1
Abbrevations: CI, confidence interval; INHANCE, International Head and Neck Cancer Epidemiology; OR, odds ratio.
a Exclusive and joint use of tobacco product(s) was defined as ever smoking/using the specified tobacco product(s) and never smoking/using
all other tobacco products.
b The Boston study (14) (500 cases and 630 controls) was excluded from analyses of exclusive and joint smokeless tobacco use because
information on snuff use was not available.
c Average durations of chewing tobacco use, snuff use, cigarette smoking, cigar smoking, and pipe smoking, respectively, among cases: 0,
0, 0, 0, and 0 years for never use of tobacco; 25.4, 0, 0, 0, and 0 years for only chewing tobacco; 0, 30.1, 0, 0, and 0 years for only snuff; 25.6,
33.2, 0, 0, and 0 years for chewing tobacco and snuff; 0, 0, 34.3, 1.9, and 1.5 years for only smoking products; 12.4, 0, 32.9, 7.6, and 4.1 years
for chewing tobacco and smoking products; 0, 12.6, 30.9, 2.5, and 1.6 years for snuff and smoking products; and 15.5, 11.8, 34.7, 7.6, and 4.9
years for chewing tobacco, snuff, and smoking products.
d Average durations of chewing tobacco use, snuff use, cigarette smoking, cigar smoking, and pipe smoking, respectively, among controls: 0,
0, 0, 0, and 0 years for never use of tobacco; 20.4, 0, 0, 0, and 0 years for only chewing tobacco; 0, 23.9, 0, 0, and 0 years for only snuff; 22.4,
25.6, 0, 0, and 0 years for chewing tobacco and snuff; 0, 0, 25.4, 2.0, and 1.8 years for only smoking products; 14.0, 0, 25.7, 7.5, and 5.8 years
for chewing tobacco and smoking products; 0, 11.5, 23.4, 2.4, and 3.1 years for snuff and smoking products; and 15.8, 14.3, 24.3, 9.2, and 7.8
years for chewing tobacco, snuff, and smoking products.
e Adjusted for sex, age (years), race/ethnicity (white, black, Hispanic, Asian and Pacific Islander, or other race/ethnicity), education (junior
high school or less, some high school, high school graduation, technical school or some college, and college graduation or more), and fre-
quency of alcohol use (mL/day, truncated at the 95th percentile among alcohol drinkers to account for extreme values).
f Never use of tobacco was defined as never smoking cigarettes, cigars, or pipes, never chewing tobacco, and never using snuff.
g Use of only smoking products was defined as ever smoking cigarettes, cigars, or pipes and never chewing tobacco or using snuff.
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(18, 47). In contrast, in 2 other studies, investigators stated
that there was no relationship between smokeless tobacco
use and the risk of HNC, though specific estimates were not
reported (17, 51). Finally, Accortt et al. (50) reported an
age-adjusted standardized incidence ratio for smokeless
tobacco and oral cavity cancer of 30 (95% CI: 3, 95), based
on only 2 users.
Few of the previous studies have examined HNC risk
based on duration and frequency of use of smokeless
tobacco. Among never cigarette smokers, Zhou et al. noted
a strong positive trend in HNC risk with increasing dura-
tion of smokeless tobacco use (Ptrend = 0.02) and a weaker
positive trend with increasing frequency (Ptrend = 0.14)
(14). Winn et al. also reported a positive trend in the risk of
gum cancers with duration of snuff use among nonsmokers;
however, similar trends were not noted for other HNC tumor
sites (45). Among studies without stratification by cigarette
smoking, Mashberg et al. (44) noted that there was no trend
in the odds ratios with respect to duration of tobacco
chewing.
When we considered tumor site-specific odds ratios
among never cigarette smokers, both snuff use and tobacco
chewing were associated with elevated risk of cancers of
the oral cavity. These associations were especially pro-
nounced for cancers of the gum, though estimates were
imprecise. In the United States, it is common practice to
place chewing tobacco or snuff between the gums and the
cheek; therefore, our finding of elevated risk for these
tumor sites is biologically plausible (8, 9). Four previous
studies reported oral cancer–specific odds ratios, with 3
studies reporting elevated, though imprecise, estimates.
Winn et al. reported gum/buccal mucosa–specific odds
ratios of 13.8 (95% CI: 1.9, 98.0) for 1–24 years of snuff
use and 47.5 (95% CI: 9.1, 249.5) for over 50 years of
snuff use (45). Williams and Horm (42) reported a gum-
and mouth-specific relative risk of 3.88 for light users of
smokeless tobacco and a relative risk of 6.65 for heavy
users. Stockwell and Lyman (43) reported an odds ratio of
11.2 (95% CI: 4.1, 30.7) for ever use of smokeless tobacco
and tumors of the gum and mouth. In contrast, Zhou et al.
reported an odds ratio of 0.90 (95% CI: 0.38, 2.12) for
using smokeless tobacco more than 20 times and oral cav-
ity cancers (14).
When we examined exclusive use, we found a weakly
elevated odds ratio for exclusive snuff use and HNC risk
but not for exclusive tobacco chewing. Use of both chew-
ing tobacco and snuff was associated with elevated HNC
risk, as was use of both smokeless and smoking tobacco
products. Since this analysis was restricted by type of
tobacco product, some cell counts were small, resulting in
imprecise estimates. We were also unable to analyze fre-
quency and duration of use among exclusive users due to
small cell counts, and as previously noted, it is possible
that exclusive users of a single tobacco product differ from
users of more than 1 product with respect to frequency and
duration. For example, in our study the mean duration of
chewing tobacco use was approximately 25.5 years among
exclusive users and among those who used both chewing
tobacco and snuff, as compared with 15.5 years among
those who used all types of tobacco. Only 1 previous
study, which was included in our pooled analysis, exam-
ined exclusive use of smokeless tobacco products; in that
study, Stingone et al. (13) reported an odds ratio of 0.9
(95% CI: 0.38, 2.07) for exclusive use of chewing tobacco
or snuff.
When we stratified analyses by age (<45 years and ≥45
years), estimates for snuff and chewing tobacco and HNC
were weakly elevated in both age groups among never cig-
arette smokers. Estimates also appeared elevated in both
white and nonwhite never cigarette smokers, with the
strongest associations being observed for snuff use and
HNC among nonwhites. Although we found elevated HNC
risk among females but not among males, smokeless tobacco
estimates stratified by sex were imprecise and should be inter-
preted with some caution. Winn et al. (45) and Blot et al. (16)
also found elevated HNC risk among female smokeless
tobacco users who were nonsmokers, and in their meta-
analysis Lee and Hamling noted higher estimates among
women, though estimates were not statistically significant
after adjustment for study period/type (33).
The major strength of our study was the large number of
cases and controls, which made it possible to estimate asso-
ciations between smokeless tobacco and HNC among never
smokers with reasonable precision. Pooling data across
studies also allowed us to better harmonize variable defini-
tions and uniformly adjust for important confounders,
namely duration of cigarette smoking and duration of use
of other smoking products. Further adjustment for frequency
of cigarette smoking and use of other smoking products did
not materially change estimates for ever snuff use or ever
tobacco chewing (data not shown). Other important contri-
butions of our study included analyses of the frequency and
duration of smokeless tobacco use, analyses of specific
tumor sites, and analyses of both exclusive and joint use of
chewing tobacco and snuff. Although some estimates were
still somewhat imprecise for a few analyses, to our knowl-
edge this was the largest and most comprehensive study to
date to estimate associations between smokeless tobacco use
and HNC in the United States.
Although response rates were relatively high across
studies, many studies selected participants from hospital
settings, which may not be as representative as population-
based studies. Further, participants were asked to retrospec-
tively recall smokeless tobacco use, which may have led to
some exposure misclassification. Although studies indicate
that people do accurately report current and past use of
tobacco products (52, 53), there remains uncertainty about
whether potential misclassification would be differential or
nondifferential between cases and controls. The prevalence
of smokeless tobacco use reported among controls in our
analysis was similar to US national estimates; 5.0% and
2.9% reported using chewing tobacco or snuff, respec-
tively, compared with an estimated 3.0% nationally (7).
Another issue related to misclassification is that people
may have had difficulty accurately reporting the type of
smokeless tobacco product (snuff vs. chewing tobacco)
they used. When we analyzed ever use of smokeless
tobacco (i.e., ever snuff use or ever tobacco chewing), we
found that the risk of HNC was weakly elevated among
never cigarette smokers (OR = 1.30, 95% CI: 0.93, 1.81)
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but not among ever cigarette smokers (OR = 0.93, 95%
CI: 0.78, 1.11). For duration and frequency, we were
unable to reliably combine values across products and
therefore did not analyze duration and frequency for com-
bined smokeless tobacco variables. Snuff can be used
orally or inhaled, though it is common to place it in the
mouth in the United States (8, 9). Therefore, we assumed
that snuff was used orally across studies in our analysis. In
the study from Baltimore (22), participants were asked
whether they ever used snuff along with a prompt regard-
ing inhalation. However, sensitivity analyses excluding the
Baltimore study, as well as all other study centers one at a
time, showed that the estimates for ever snuff use were
robust. Other limitations of our study included the follow-
ing: We were unable to consider current versus former use
of smokeless tobacco products, including ages at starting
and stopping, as well as type (e.g., brand of chewing
tobacco and dry snuff vs. wet snuff) and amount (e.g.,
grams) of smokeless tobacco used, because many studies
included in our analysis did not collect this information;
our models did not account for human papillomavirus
infection, because many studies also did not contain this
information; approximately 3.4% of individuals were miss-
ing information on duration of alcohol use and were there-
fore excluded from analyses; and the main analyses
included cases who had tumors with a histological type
other than squamous cell carcinoma (15.4%), though odds
ratios for ever tobacco chewing and ever snuff use and
HNC restricted to squamous cell carcinoma were similar to
the estimates from the main analyses.
In the United States, smokeless tobacco is commonly
used orally, which directly exposes tissues in the oral cav-
ity, pharynx, and larynx to a number of carcinogens,
including tobacco-specific N-nitrosamines, N-nitrosamino
acids, volatile N-nitrosamines, and polycyclic aromatic hy-
drocarbons, which have been shown to disrupt DNA repair,
among other molecular processes (9). We found robust evi-
dence of elevated risk of HNC associated with snuff use
among never cigarette smokers across various sets of
adjustment variables and when analysis was restricted to
cancers of the oral cavity. Associations between chewing
tobacco and HNC were less consistent. Main analyses
among never cigarette smokers showed weak associations
which were attenuated towards the null when adjusted for
snuff use, while analyses restricted to cancers of the oral
cavity showed stronger associations. Additional large stud-
ies which examine smokeless tobacco use separately from
joint smoking and smokeless tobacco use are needed to
more precisely estimate associations with HNC among
both types of users. Studies that included a larger number
of individuals from minority populations within the United
States, as well as studies of international populations,
would further contribute to the existing literature. In addi-
tion, studies which focus on high-risk groups (e.g., the con-
struction and mining industries, where US prevalence of
smokeless tobacco use is 7.9% and 18.8%, respectively
(7)), may further elucidate associations between smokeless
tobacco use and HNC risk and offer insight into exposure
and disease reduction.
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